# Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

> **NCT00303745** · PHASE2 · UNKNOWN · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 78 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00303745
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2008-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00303745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00303745, "Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00303745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*